Keep an eye on Structure Therapeutics (SYM: GPCR).
According to JPMorgan, it’s an overlooked player in the weight loss treatment market. The firm has an overweight rating on the stock, with a price target of $65.
“We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035,” added the firm, as quoted by CNBC. “GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.”
Helping, interest in weight loss medications is through the roof. In fact, according to Goldman Sachs, at current pace the market could be worth about $100 billion by 2030.